Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-β receptor protein expressions

Journal of the American Society of Nephrology

Volumn 7, Issue 8, 1996, Pages 1207-1215

  Guh, Jinn Yuh ^a   Yang, Mei Li ^a   Yang, Yu Lin ^a   Chang, Chun Chang ^a   Chuang, Lea Yea ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Captopril; Diabetic nephropathy; Transforming growth factor

Indexed keywords

CAPTOPRIL; GLUCOSE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG MECHANISM; KIDNEY FAILURE; KIDNEY HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SWINE;

EID: 0030410472     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hostetter TH. Diabetic nephropathy. In: Brenner BM, Rector RC, Eds. The Kidney. 4th Ed. Philadelphia: WB Saunders; 1991:1695-1727.
2. Schwieger J, Fine LG: Renal hypertrophy, growth factors and nephropathy in diabetes mellitus. Semin Nephrol 1990;10:242-253.
3. Striker GE, Peten EP, Caromen MA, et al.: The kidney disease of diabetes mellitus (KDDM): A cell and molecular biology approach. Diabetes Metab Rev 1993;9:37-56.
4. 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 1983; 25:280-287.
5. Young BA, Johnson RJ, Alpers CE, et al.: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-944.
6. Nakamura T, Fukui M, Ebihara I, et al.: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;42:450-456.
7. Guh JY, Lai YH, Shin SJ, Chuang LY, Tsai JH: Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats. Nephron 1991;59:641-647.
8. Lee YJ, Shin SJ, Lin SR, Tsai JH: Increased expression of heparin binding epidermal-growth-factor-like growth factor mRNA in the kidney of streptozotocin-diabetic rats. Biochem Biophys Res Commun 1995;207:216-222.
9. Flyvbjerg A: Growth factors and diabetic complications. Diabetic Med 1990;7:387-399.
10. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
11. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994;266[Pt 2]:F829-F842.
12. Border WA, Brees D, Noble NA: Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contr Nephrol 1994;107:140-145.
13. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
14. Humes HD, Beals TF, Cieslinski DA, Sanchez IO, Page TP: Effects of transforming growth factor-beta, transforming growth factor-alpha, and other growth factors on renal proximal tubule cells. Lab Invest 1991;64:538-545.
15. Fine LG, Holley RW, Nasri H, Badie-Dezfooly B: BSC-1 growth inhibitor transforms a mitogenic stimulus into a hypertrophic stimulus for renal proximal tubular cells: Relationship to Na+/H+ antiport activity. Proc Natl Acad Sci USA 1985;82:6163-6166.
16. Shankland SJ, Scholey JW, Ly H, Thai K: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidnev Int 1994;46:430-442.
17. Miyazono K, Ten Dijke P, Ichijo H, Heldin CH: Receptors for transforming growth factor-beta. Adv Immunol 1994; 55:181-220.
18. Lin HY, Moustakas A: TGF-beta receptors: Structure and function. Cell Mol Biol 1994;40:337-349.
19. Derynck R: TGF-beta-receptor-mediated signaling. Trends Biochem Sci 1994;19:548-553.
20. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-347.
21. Molitch ME: ACE inhibitors and diabetic nephropathy. Diabetes Care 1994;17:756-760.
22. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-814.
23. Hollenberg NK, Raij L: Angiotensin-converting enzyme inhibition and renal protection: An assessment of implications for therapy. Arch Intern Med 1993;153:2426-2435.
24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
25. Hajinazarian M, Cosio FG, Nahman S, Mahan JD: Angiotensin-converting enzyme inhibition partially prevents diabetic organomegaly. Am J Kidney Dis 1994;23: 105-117.
26. Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int 1993;39[Suppl]:S100-S107.
27. Wolf G, Zahner G, Mondorf U, Schoeppe W, Stahl RA: Angiotensin II stimulates cellular hypertrophy of LLC-PK1 cells through the AT1 receptor. Nephrol Dial Transplant 1993;8:128-133.
28. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993;92:1366-1372.
29. Ziyadeh FN, Snipes ER, Watanabe M, Alvarez RJ, Goldfarb S, Haverty TP: High glucose induces cell hypertrophy and stimulates collagen gene expression in proximal tubule. Am J Physiol 1990;259:F704-F714.
30. Krisberg JI: Hyperglycemia and microangiopathy: Direct regulation by glucose of microvascular cells. Lab Invest 1992;67:416-426.
31. Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991;39:464-475.
32. Moe OW, Ujiie K, Star RA, et al.: Renin expression in renal proximal tubule. J Clin Invest 1993;91:774-779.
33. + exchange is not required for induction of hypertrophy of renal cells in vitro. J Am Soc Nephrol 1992;3:1124-1130.
34. Derynck R, Rhee L: Sequence of the porcine transforming growth factor-beta precursor. Nucleic Acids Res 1987;15:3187.
35. Tokunaga K, Taniguchi H, Yoda K, Shimizu M, Sakiyama S: Nucleotide sequence of a full-length cDNA for mouse cytoskeletal β-actin mRNA. Nucleic Acids Res 1986;14:2829.
36. Chuang LY, Hung WC, Chang CC, Tsai JH: Characterization of apoptosis induced by transforming growth factor beta 1 in human hepatoma cells. Anticancer Res 1994;14:147-152.
37. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
38. Fine LG: The biology of renal hypertrophy. Kidney Int 1986;29:619-634.
39. Kressel G, Bohle A, Muller CA, Muller GA: The pathogenesis of chronic renal failure. Pathol Res Pract 1989; 85:421-440.
40. Jerums R, Gilbert R: Renal tubular dysfunction in diabetes mellitus. Diabetes Ann 1993;7:146-165.
41. Fukui M, Nakamura T, Ebihara I, et al.: Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 1994;123: 763-768.
42. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107-114.
43. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;7:25-49.
44. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J: Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and non-sulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-333.
45. Trachtman H, Futterweit S, Prenner J, Hanon S: Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun 1994;199:346-352.
46. Brogden RN, Todd PA, Sorkin EM: Captopril: An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988;36:540-600.
47. 32S-captopril in rats after intravenous and oral administration. Xenobiotica 1985;15: 51-56.
48. 86Rb) influx and cellular proliferation. Clin Chim Acta 1990;187:47-53.
49. Andreoli SP: Captopril scavenges hydrogen peroxide and reduces, but does not eliminate, oxidant-induced cell injury. Am J Physiol 1993;264:F120-F127.